Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Out at first homolog (OAF) is a protein-coding gene in humans associated with the production of a protein of approximately 273 amino acids and a mass of 30.7 kDa. The gene is also known as HCV NS5A-transactivated protein 13 target protein 2. Diseases associated with mutations or changes in OAF include spondylocarpotarsal synostosis syndrome and pleuropneumonia. The molecular function, physiological role, and mechanism of action for OAF remain poorly characterized, and there is no evidence that it functions as a traditional therapeutic target such as a receptor, enzyme, or transporter. No drug interactions, mechanisms of action, or known biomarkers have been documented for OAF. Its subcellular localization and functional pathways are not well-defined in current resources. If you need further information on functional studies or a more detailed molecular annotation, additional specialized biochemical or genetic literature may need to be consulted.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Out at first homolog (OAF).